Base de dados : MEDLINE
Pesquisa : D20.215.894.135.750 [Categoria DeCS]
Referências encontradas : 530 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 53 ir para página                         

  1 / 530 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351318
[Au] Autor:Sigaúque B; Kobayashi M; Vubil D; Nhacolo A; Chaúque A; Moaine B; Massora S; Mandomando I; Nhampossa T; Bassat Q; Pimenta F; Menéndez C; Carvalho MDG; Macete E; Schrag SJ
[Ad] Endereço:Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
[Ti] Título:Invasive bacterial disease trends and characterization of group B streptococcal isolates among young infants in southern Mozambique, 2001-2015.
[So] Source:PLoS One;13(1):e0191193, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Maternal group B streptococcal (GBS) vaccines under development hold promise to prevent GBS disease in young infants. Sub-Saharan Africa has the highest estimated disease burden, although data on incidence and circulating strains are limited. We described invasive bacterial disease (IBD) trends among infants <90 days in rural Mozambique during 2001-2015, with a focus on GBS epidemiology and strain characteristics. METHODS: Community-level birth and mortality data were obtained from Manhiça's demographic surveillance system. IBD cases were captured through ongoing surveillance at Manhiça district hospital. Stored GBS isolates from cases underwent serotyping by multiplex PCR, antimicrobial susceptibility testing, and whole genome sequencing. RESULTS: There were 437 IBD cases, including 57 GBS cases. Significant declines in overall IBD, neonatal mortality, and stillbirth rates were observed (P<0.0001), but not for GBS (P = 0.17). In 2015, GBS was the leading cause of young infant IBD (2.7 per 1,000 live births). Among 35 GBS isolates available for testing, 31 (88.6%) were highly related serotype III isolates within multilocus sequence types (STs) 17 (68.6%) or 109 (20.0%). All seven ST109 isolates (21.9%) had elevated minimum inhibitory concentration (MIC) to penicillin (≥0.12 µg/mL) associated with penicillin-binding protein (PBP) 2x substitution G398A. Epidemiologic and molecular data suggest this is a well-established clone. CONCLUSION: A notable young infant GBS disease burden persisted despite improvements in overall maternal and neonatal health. We report an established strain with pbp2x point mutation, a first-step mutation associated with reduced penicillin susceptibility within a well-known virulent lineage in rural Mozambique. Our findings further underscores the need for non-antibiotic GBS prevention strategies.
[Mh] Termos MeSH primário: Infecções Bacterianas/epidemiologia
Infecções Estreptocócicas/epidemiologia
Infecções Estreptocócicas/microbiologia
Streptococcus agalactiae
[Mh] Termos MeSH secundário: Idade de Início
Feminino
Genoma Bacteriano
Seres Humanos
Imunidade Materno-Adquirida
Incidência
Lactente
Recém-Nascido
Masculino
Testes de Sensibilidade Microbiana
Moçambique/epidemiologia
Reação em Cadeia da Polimerase Multiplex
Resistência às Penicilinas/genética
Proteínas de Ligação às Penicilinas/genética
Mutação Puntual
Gravidez
Estudos Retrospectivos
Sorotipagem
Infecções Estreptocócicas/prevenção & controle
Vacinas Estreptocócicas/farmacologia
Streptococcus agalactiae/efeitos dos fármacos
Streptococcus agalactiae/genética
Streptococcus agalactiae/isolamento & purificação
Virulência/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Penicillin-Binding Proteins); 0 (Streptococcal Vaccines); 128284-03-7 (PBP 2x protein, Streptococcus)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191193


  2 / 530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28923133
[Au] Autor:Teatero S; Neemuchwala A; Yang K; Gomes J; Athey TBT; Martin I; Demczuk W; McGeer A; Fittipaldi N
[Ad] Endereço:1​Public Health Ontario, Toronto, ON, Canada.
[Ti] Título:Genetic evidence for a novel variant of the pilus island 1 backbone protein in group B Streptococcus.
[So] Source:J Med Microbiol;66(10):1409-1415, 2017 Oct.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Pili contribute significantly to the pathogenesis of infection of group B Streptococcus (GBS) by facilitating adhesion and invasion of host cells. GBS pilin subunits (the backbone pilin protein, BP, and the ancillary pilin proteins, AP) as well as the specific enzymes required for pilus assembly are encoded by genes located in two separate genomic regions, known as pilus island 1 (PI-1) and PI-2. Our aim was to characterize the pilus profile of a collection of GBS isolates from metropolitan Toronto, Canada. METHODOLOGY: The pilus profile of 1332 invasive and colonizing GBS isolates was determined by PCR and, in selected cases, by whole genome sequencing. RESULTS: While investigating the pilus profile of a collection of GBS organisms, we discovered that 51 isolates possessed a novel variant of the PI-1 BP, which we named BP-1b. The predicted translated sequences of archetypical GBS BP-1 and novel BP-1b variants shared only 63 % amino acid sequence homology. The novel BP-1b variant was most common among strains of serotype Ib and VI, but was also found among strains of serotypes Ia, II, III and VIII. CONCLUSION: We describe a relatively frequent occurrence of a novel PI-1 BP that cannot be detected by a commonly used multiplex PCR scheme, which could lead to strains being mistyped as PI-1 negative. We present PCR primers that can easily be incorporated into the multiplex PCR assay to identify strains with novel BP-1b variant.
[Mh] Termos MeSH primário: Proteínas de Bactérias/metabolismo
Fímbrias Bacterianas/metabolismo
Variação Genética
Família Multigênica
Streptococcus agalactiae/genética
Transcriptoma
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Proteínas de Bactérias/genética
Fímbrias Bacterianas/genética
Regulação Bacteriana da Expressão Gênica/fisiologia
Seres Humanos
Infecções Estreptocócicas/microbiologia
Infecções Estreptocócicas/prevenção & controle
Vacinas Estreptocócicas/imunologia
Streptococcus agalactiae/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Streptococcal Vaccines)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170920
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000588


  3 / 530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28904125
[Au] Autor:Nordström T; Pandey M; Calcutt A; Powell J; Phillips ZN; Yeung G; Giddam AK; Shi Y; Haselhorst T; von Itzstein M; Batzloff MR; Good MF
[Ad] Endereço:The QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia; and.
[Ti] Título:Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.
[So] Source:J Immunol;199(8):2794-2802, 2017 Oct 15.
[Is] ISSN:1550-6606
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Peptides offer enormous promise as vaccines to prevent and protect against many infectious and noninfectious diseases. However, to date, limited vaccine efficacy has been reported and none have been licensed for human use. Innovative ways to enhance their immunogenicity are being tested, but rational sequence modification as a means to improve immune responsiveness has been neglected. Our objective was to establish a two-step generic protocol to modify defined amino acids of a helical peptide epitope to create a superior immunogen. Peptide variants of p145, a conserved helical peptide epitope from the M protein of , were designed by exchanging one amino acid at a time, without altering their α-helical structure, which is required for correct antigenicity. The immunogenicities of new peptides were assessed in outbred mice. Vaccine efficacy was assessed in a skin challenge and invasive disease model. Out of 86 variants of p145, seven amino acid substitutions were selected and made the basis of the design for 18 new peptides. Of these, 13 were more immunogenic than p145; 7 induced Abs with significantly higher affinity for p145 than Abs induced by p145 itself; and 1 peptide induced more than 10,000-fold greater protection following challenge than the parent peptide. This peptide also only required a single immunization (compared with three immunizations with the parent peptide) to induce complete protection against invasive streptococcal disease. This study defines a strategy to rationally improve the immunogenicity of peptides and will have broad applicability to the development of vaccines for infectious and noninfectious diseases.
[Mh] Termos MeSH primário: Antígenos de Bactérias/metabolismo
Proteínas da Membrana Bacteriana Externa/metabolismo
Proteínas de Transporte/metabolismo
Fragmentos de Peptídeos/metabolismo
Infecções Estreptocócicas/imunologia
Vacinas Estreptocócicas/imunologia
Streptococcus pyogenes/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Antibacterianos/sangue
Antígenos de Bactérias/genética
Antígenos de Bactérias/imunologia
Proteínas da Membrana Bacteriana Externa/genética
Proteínas da Membrana Bacteriana Externa/imunologia
Proteínas de Transporte/genética
Proteínas de Transporte/imunologia
Seres Humanos
Imunidade Humoral
Imunização
Camundongos
Camundongos Endogâmicos BALB C
Mutação/genética
Fragmentos de Peptídeos/genética
Fragmentos de Peptídeos/imunologia
Engenharia de Proteínas
Infecções Estreptocócicas/prevenção & controle
Vacinas de Subunidades
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Antigens, Bacterial); 0 (Bacterial Outer Membrane Proteins); 0 (Carrier Proteins); 0 (Peptide Fragments); 0 (Streptococcal Vaccines); 0 (Vaccines, Subunit); 0 (streptococcal M protein)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE
[do] DOI:10.4049/jimmunol.1700836


  4 / 530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28433705
[Au] Autor:Marchant A; Sadarangani M; Garand M; Dauby N; Verhasselt V; Pereira L; Bjornson G; Jones CE; Halperin SA; Edwards KM; Heath P; Openshaw PJ; Scheifele DW; Kollmann TR
[Ad] Endereço:Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: arnaud.marchant@ulb.ac.be.
[Ti] Título:Maternal immunisation: collaborating with mother nature.
[So] Source:Lancet Infect Dis;17(7):e197-e208, 2017 Jul.
[Is] ISSN:1474-4457
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Maternal immunisation has the potential to substantially reduce morbidity and mortality from infectious diseases after birth. The success of tetanus, influenza, and pertussis immunisation during pregnancy has led to consideration of additional maternal immunisation strategies to prevent group B streptococcus and respiratory syncytial virus infections, among others. However, many gaps in knowledge regarding the immunobiology of maternal immunisation prevent the optimal design and application of this successful public health intervention. Therefore, we did an innovative landscape analysis to identify research priorities. Key topics were delineated through review of the published literature, consultation with vaccine developers and regulatory agencies, and a collaborative workshop that gathered experts across several maternal immunisation initiatives-group B streptococcus, respiratory syncytial virus, pertussis, and influenza. Finally, a global online survey prioritised the identified knowledge gaps on the basis of expert opinion about their importance and relevance. Here we present the results of this worldwide landscape analysis and discuss the identified research gaps.
[Mh] Termos MeSH primário: Imunidade Materno-Adquirida
Imunização/métodos
Complicações Infecciosas na Gravidez/prevenção & controle
[Mh] Termos MeSH secundário: Países em Desenvolvimento
Feminino
Saúde Global
Seres Humanos
Imunização/utilização
Vacinas contra Influenza/administração & dosagem
Influenza Humana/prevenção & controle
Gravidez
Complicações Infecciosas na Gravidez/imunologia
Cuidado Pré-Natal/métodos
Infecções por Vírus Respiratório Sincicial/prevenção & controle
Vacinas contra Vírus Sincicial Respiratório/administração & dosagem
Infecções Estreptocócicas/microbiologia
Infecções Estreptocócicas/prevenção & controle
Vacinas Estreptocócicas/administração & dosagem
Streptococcus agalactiae/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Influenza Vaccines); 0 (Respiratory Syncytial Virus Vaccines); 0 (Streptococcal Vaccines)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170424
[St] Status:MEDLINE


  5 / 530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28433702
[Au] Autor:Heath PT; Culley FJ; Jones CE; Kampmann B; Le Doare K; Nunes MC; Sadarangani M; Chaudhry Z; Baker CJ; Openshaw PJM
[Ad] Endereço:Vaccine Institute, Institute for Infection and Immunity, St George's, University of London and St George's University Hospitals NHS Foundation Trust, London, UK. Electronic address: pheath@sgul.ac.uk.
[Ti] Título:Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis.
[So] Source:Lancet Infect Dis;17(7):e223-e234, 2017 Jul.
[Is] ISSN:1474-4457
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Group B streptococcus and respiratory syncytial virus are leading causes of infant morbidity and mortality worldwide. No licensed vaccines are available for either disease, but vaccines for both are under development. Severe respiratory syncytial virus disease can be prevented by passively administered antibody. The presence of maternal IgG antibody specific to respiratory syncytial virus is associated with reduced prevalence and severity of respiratory syncytial virus disease in the first few weeks of life, whereas maternal serotype-specific anticapsular antibody is associated with protection against both early-onset and late-onset group B streptococcus disease. Therefore, vaccination in pregnancy might protect infants against both diseases. This report describes what is known about immune protection against group B streptococcus and respiratory syncytial virus, identifies knowledge gaps regarding the immunobiology of both diseases, and aims to prioritise research directions in maternal immunisation.
[Mh] Termos MeSH primário: Imunidade Materno-Adquirida
Imunização/métodos
Infecções por Vírus Respiratório Sincicial/prevenção & controle
Vacinas contra Vírus Sincicial Respiratório/administração & dosagem
Infecções Estreptocócicas/prevenção & controle
Vacinas Estreptocócicas/administração & dosagem
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Imunização/utilização
Lactente
Gravidez
Infecções por Vírus Respiratório Sincicial/imunologia
Vírus Sincicial Respiratório Humano/efeitos dos fármacos
Vírus Sincicial Respiratório Humano/imunologia
Infecções Estreptocócicas/microbiologia
Streptococcus agalactiae/isolamento & purificação
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Respiratory Syncytial Virus Vaccines); 0 (Streptococcal Vaccines)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170424
[St] Status:MEDLINE


  6 / 530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28414746
[Au] Autor:Mortensen R; Christensen D; Hansen LB; Christensen JP; Andersen P; Dietrich J
[Ad] Endereço:Statens Serum Institut, Department of Infectious Disease Immunology, Copenhagen, Denmark.
[Ti] Título:Local Th17/IgA immunity correlate with protection against intranasal infection with Streptococcus pyogenes.
[So] Source:PLoS One;12(4):e0175707, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Streptococcus pyogenes (group A streptococcus, GAS) is responsible for a wide array of infections. Respiratory transmission via droplets is the most common mode of transmission but it may also infect the host via other routes such as lesions in the skin. To advance the development of a future vaccine against GAS, it is therefore important to investigate how protective immunity is related to the route of vaccine administration. To explore this, we examined whether a parenterally administered anti-GAS vaccine could protect against an intranasal GAS infection or if this would require locally primed immunity. We foundd that a parenteral CAF01 adjuvanted GAS vaccine offered no protection against intranasal infection despite inducing strong systemic Th1/Th17/IgG immunity that efficiently protected against an intraperitoneal GAS infection. However, the same vaccine administered via the intranasal route was able to induce protection against repeated intranasal GAS infections in a murine challenge model. The lack of intranasal protection induced by the parenteral vaccine correlated with a reduced mucosal recall response at the site of infection. Taken together, our results demonstrate that locally primed immunity is important for the defense against intranasal infection with Streptococcus pyogenes.
[Mh] Termos MeSH primário: Imunoglobulina A/metabolismo
Infecções Estreptocócicas/imunologia
Infecções Estreptocócicas/prevenção & controle
Streptococcus pyogenes
Células Th17/imunologia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/administração & dosagem
Administração Intranasal
Animais
Anticorpos Antibacterianos/biossíntese
Feminino
Imunidade Celular
Imunidade nas Mucosas
Imunoglobulina G/biossíntese
Injeções Subcutâneas
Pulmão/imunologia
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Endogâmicos C57BL
Vacinas Estreptocócicas/administração & dosagem
Streptococcus pyogenes/imunologia
Células Th1/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Bacterial); 0 (Immunoglobulin A); 0 (Immunoglobulin G); 0 (Streptococcal Vaccines)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170509
[Lr] Data última revisão:
170509
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170418
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0175707


  7 / 530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28355251
[Au] Autor:Kuo CF; Tsao N; Hsieh IC; Lin YS; Wu JJ; Hung YT
[Ad] Endereço:Department of Nursing, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
[Ti] Título:Immunization with a streptococcal multiple-epitope recombinant protein protects mice against invasive group A streptococcal infection.
[So] Source:PLoS One;12(3):e0174464, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Streptococcus pyogenes (group A Streptococcus; GAS) causes clinical diseases, including pharyngitis, scarlet fever, impetigo, necrotizing fasciitis and streptococcal toxic shock syndrome. A number of group A streptococcus vaccine candidates have been developed, but only one 26-valent recombinant M protein vaccine has entered clinical trials. Differing from the design of a 26-valent recombinant M protein vaccine, we provide here a vaccination using the polyvalence epitope recombinant FSBM protein (rFSBM), which contains four different epitopes, including the fibronectin-binding repeats domain of streptococcal fibronectin binding protein Sfb1, the C-terminal immunogenic segment of streptolysin S, the C3-binding motif of streptococcal pyrogenic exotoxin B, and the C-terminal conserved segment of M protein. Vaccination with the rFSBM protein successfully prevented mortality and skin lesions caused by several emm strains of GAS infection. Anti-FSBM antibodies collected from the rFSBM-immunized mice were able to opsonize at least six emm strains and can neutralize the hemolytic activity of streptolysin S. Furthermore, the internalization of GAS into nonphagocytic cells is also reduced by anti-FSBM serum. These findings suggest that rFSBM can be applied as a vaccine candidate to prevent different emm strains of GAS infection.
[Mh] Termos MeSH primário: Infecções Estreptocócicas/prevenção & controle
Vacinas Estreptocócicas/administração & dosagem
Streptococcus pyogenes/imunologia
Vacinação
Vacinas Sintéticas/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Proteínas de Bactérias/biossíntese
Proteínas de Bactérias/genética
Proteínas de Bactérias/imunologia
Sequência de Bases
Cisteína Endopeptidases/biossíntese
Cisteína Endopeptidases/genética
Cisteína Endopeptidases/imunologia
Epitopos
Escherichia coli
Feminino
Camundongos Endogâmicos BALB C
Proteínas Recombinantes/biossíntese
Proteínas Recombinantes/genética
Proteínas Recombinantes/imunologia
Infecções Estreptocócicas/imunologia
Infecções Estreptocócicas/microbiologia
Vacinas Estreptocócicas/imunologia
Potência de Vacina
Vacinas Sintéticas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); 0 (Epitopes); 0 (Recombinant Proteins); 0 (Streptococcal Vaccines); 0 (Vaccines, Synthetic); EC 3.4.22.- (Cysteine Endopeptidases); EC 3.4.22.10 (streptopain)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170825
[Lr] Data última revisão:
170825
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170330
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0174464


  8 / 530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28219739
[Au] Autor:Zhang Z; Yu A; Lan J; Zhang H; Hu M; Cheng J; Zhao L; Lin L; Wei S
[Ad] Endereço:Department of Aquatic Animal Medicine, Research Center for Marine Biology, College of Fisheries, Huazhong Agricultural University, Wuhan, Hubei, 430070, China; School of Life Sciences, Beijing Normal University, Beijing, 100875, China; National Institute of Biological Sciences, Zhongguancun Life Sci
[Ti] Título:GapA, a potential vaccine candidate antigen against Streptococcus agalactiae in Nile tilapia (Oreochromis niloticus).
[So] Source:Fish Shellfish Immunol;63:255-260, 2017 Apr.
[Is] ISSN:1095-9947
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Streptococcosis due to the bacterium Streptococcus agalactiae (S. agalactiae) has resulted in enormous economic losses in aquaculture worldwide, especially in the tilapia culture industry. Previously, there were limited vaccines that could be employed against streptococcosis in tilapia. This study aimed to develop a vaccine candidate using the glyceraldehyde-phosphate dehydrogenase protein (GapA) of S. agalactiae encoded by the gapA gene. Tilapia were intraperitoneally injected with PBS, PBS + Freund's adjuvant, PBS + Montanide's adjuvant, GapA + Freund's adjuvant, GapA + Montanide's adjuvant, killed S. agalactiae whole cells (WC)+Freund's adjuvant, or killed S. agalactiae whole cells (WC)+ Montanide's adjuvant. They were then challenged with S. agalactiae, and the relative percentage survival (RPS) was monitored 14 days after the challenge. The highest RPSs were observed in the WC groups, with 76.7% in WC + Freund's adjuvant and 74.4% in WC + Montanide's adjuvant groups; these were followed by the GapA groups, with 63.3% in GapA + Freund's adjuvant and 45.6% in GapA + Montanide's adjuvant groups. The RPS of the PBS group was 0%, and those of PBS + Freund's adjuvant and PBS + Montanide's adjuvant groups were 6.7% and 3.3%, respectively. Additionally, the IgM antibody responses elicited in GapA groups and WC groups were significantly higher than those in PBS groups. Furthermore, the expressions of cytokine (IL-1ß and TNF-α) mRNAs in the GapA groups and WC groups were significantly higher than those in the PBS groups. Taken together, these results reveal that the GapA protein is a promising vaccine candidate that could be used to prevent streptococcosis in tilapia.
[Mh] Termos MeSH primário: Adesinas Bacterianas/imunologia
Ciclídeos
Doenças dos Peixes/prevenção & controle
Infecções Estreptocócicas/veterinária
Vacinas Estreptocócicas/imunologia
Streptococcus agalactiae/imunologia
[Mh] Termos MeSH secundário: Animais
Clonagem Molecular
Escherichia coli/genética
Doenças dos Peixes/imunologia
Doenças dos Peixes/microbiologia
Injeções Intraperitoneais/veterinária
Organismos Geneticamente Modificados/genética
Distribuição Aleatória
Infecções Estreptocócicas/imunologia
Infecções Estreptocócicas/microbiologia
Infecções Estreptocócicas/prevenção & controle
Vacinas Estreptocócicas/genética
Vacinas de Subunidades/genética
Vacinas de Subunidades/imunologia
Vacinas Sintéticas/genética
Vacinas Sintéticas/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adhesins, Bacterial); 0 (GapA cytadhesin); 0 (Streptococcal Vaccines); 0 (Vaccines, Subunit); 0 (Vaccines, Synthetic)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170501
[Lr] Data última revisão:
170501
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE


  9 / 530 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28179116
[Au] Autor:Song B; Yang X; Sun H; Yu L; Ma J; Wu Z; Cui Y
[Ad] Endereço:College of Life Science and Biotechnology, Heilingjiang Bayi Agricultural University, Daqing, Heilongjiang Province, China.
[Ti] Título:Immunogenicity of amino acids 1-150 of Streptococcus GapC displayed on the surface of Escherichia coli.
[So] Source:Microb Pathog;105:288-297, 2017 Apr.
[Is] ISSN:1096-1208
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Streptococcus is one of the main pathogens that cause bovine mastitis. They includes into S.agalactiae, S.dysgalactiae, and S.uberis. The GapC protein is a virulence factor that is expressed on the surface of Streptococcus species. GapC is highly antigenic and immunization with GapC confers cross-protection against all three species. Our previous data showed that amino acids 1-150 of GapC (GapC ) of S. dysgalactiae conferred similar immunoprotection compared to full-length GapC. Thus, the present study aimed to construct a recombinant Escherichia coli XL1-Blue strain that displayed GapC on its surface, and to investigate the immunogenicity of the surface-localized GapC . To do so, the ompA gene of the E. coli XL1-Blue strain was replaced with the lpp'-ompA-gapC1 or lpp'-ompA genes by λ Red recombination, the former of which fused GapC to an Lpp lipoprotein signal peptide and amino acids 1-159 of OmpA; the recombinant strains were named XL1-Blue/LOG76 and XL1-Blue/LO11, respectively. GapC was confirmed to localize to the surface of the XL1-Blue/LOG76 strain by an indirect enzyme-linked immunosorbent assay (ELISA), a fluorescence-activated cell sorter analysis, and laser-scanning confocal microscopy. Then, ICR mice were immunized intramuscularly with the XL1-Blue/LOG76 or XL1-Blue/LO11 strains, or recombinant GapC . The sera of the immunized mice were collected and the anti-GapC antibody levels were detected by ELISA. Lymphocytes secreting interleukin (IL)-4 and interferon-γ were detected by an enzyme-linked ImmunoSpot assay, as was the level of IL-17A level in the supernatant of cultured splenic lymphocytes. The mice immunized with the XL1-Blue/LOG76 strain or GapC exhibited better cellular and humoral immunity. Lastly, the immunized mice were challenged with S. uberis, S. dysgalactiae, and S. agalactiae strains, and mice that were immunized with the XL1-Blue/LOG76 strain were better protected than those that were immunized with the XL1-Blue/LO11 strain. These results indicate that it is feasible to display GapC on the E. coli surface as a vaccine against Streptococcus species.
[Mh] Termos MeSH primário: Antígenos de Bactérias/imunologia
Proteínas de Bactérias/imunologia
Vacinas Estreptocócicas/imunologia
Streptococcus/imunologia
[Mh] Termos MeSH secundário: Aminoácidos/genética
Aminoácidos/imunologia
Animais
Antígenos de Bactérias/química
Antígenos de Bactérias/genética
Proteínas da Membrana Bacteriana Externa/biossíntese
Proteínas da Membrana Bacteriana Externa/genética
Proteínas da Membrana Bacteriana Externa/imunologia
Proteínas de Bactérias/química
Proteínas de Bactérias/genética
Sequência de Bases
Bovinos
Citocinas/imunologia
DNA Bacteriano/isolamento & purificação
Escherichia coli/genética
Escherichia coli/imunologia
Escherichia coli/metabolismo
Interferon gama/sangue
Interleucina-17/sangue
Interleucina-4/sangue
Mastite Bovina/microbiologia
Camundongos
Camundongos Endogâmicos ICR
Modelos Animais
Fragmentos de Peptídeos/química
Fragmentos de Peptídeos/genética
Fragmentos de Peptídeos/imunologia
Proteínas Recombinantes de Fusão/biossíntese
Proteínas Recombinantes de Fusão/genética
Proteínas Recombinantes de Fusão/imunologia
Vacinas Estreptocócicas/genética
Streptococcus/genética
Vacinas de Subunidades/genética
Vacinas de Subunidades/imunologia
Fatores de Virulência/genética
Fatores de Virulência/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amino Acids); 0 (Antigens, Bacterial); 0 (Bacterial Outer Membrane Proteins); 0 (Bacterial Proteins); 0 (Cytokines); 0 (DNA, Bacterial); 0 (GapC protein, Streptococcus); 0 (Interleukin-17); 0 (Peptide Fragments); 0 (Recombinant Fusion Proteins); 0 (Streptococcal Vaccines); 0 (Vaccines, Subunit); 0 (Virulence Factors); 149024-69-1 (OMPA outer membrane proteins); 207137-56-2 (Interleukin-4); 82115-62-6 (Interferon-gamma)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170505
[Lr] Data última revisão:
170505
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170210
[St] Status:MEDLINE


  10 / 530 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28131383
[Au] Autor:Hsueh KJ; Chen MC; Cheng LT; Lee JW; Chung WB; Chu CY
[Ad] Endereço:Department of Veterinary Medicine, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung, 91201 Taiwan; Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung, 91201
[Ti] Título:Transcutaneous immunization of Streptococcus suis bacterin using dissolving microneedles.
[So] Source:Comp Immunol Microbiol Infect Dis;50:78-87, 2017 Feb.
[Is] ISSN:1878-1667
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Vaccine delivery using microneedle (MN) patches is an easy, safe and painless alternative to traditional needle injections. In this study, we examined whether MN patches can enhance the efficacy of a Streptococcus suis serotype 2 (S. suis 2) vaccine in a mouse model. Results showed that MNs can reach 200-250µm into the skin, a depth beneficial for targeted delivery of antigens to antigen-presenting cells in the epidermis and dermis. Vaccination with prime-boost of MN induced higher levels of IgG2a antibody titer, T cell proliferation, and T 1 cytokines (IFN-γ and IL-12) as compared to intramuscular (IM) injection. In addition, single dose MN vaccination better protected mice against lethal challenge than IM vaccination. MN vaccination also conferred long-term IgG2a antibody against S. suis 2 bacteria presence for up to 7 months. Taken together, these data showed that vaccine delivery by MNs results in superior immune response and protection rate when compared to IM injections.
[Mh] Termos MeSH primário: Pele/imunologia
Infecções Estreptocócicas/imunologia
Vacinas Estreptocócicas/administração & dosagem
Streptococcus suis/imunologia
Vacinação/métodos
[Mh] Termos MeSH secundário: Administração Cutânea
Animais
Citocinas/sangue
Citocinas/imunologia
Esquemas de Imunização
Imunoglobulina G/sangue
Injeções Intramusculares
Camundongos
Camundongos Endogâmicos BALB C
Microinjeções/métodos
Agulhas
Infecções Estreptocócicas/prevenção & controle
Células Th1/imunologia
Adesivo Transdérmico
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cytokines); 0 (Immunoglobulin G); 0 (Streptococcal Vaccines)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170217
[Lr] Data última revisão:
170217
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170130
[St] Status:MEDLINE



página 1 de 53 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde